We examined the loss of expression and the promoter methylation of MGMT in 149 gastric carcinomas and 11 gastric cancer cell lines and investigated an association with loss of expression and clinicopathological characteristics in consecutive gastric carcinomas. This evidence concerns the gene MGMT and gastric cancer.